Computational modeling of ketamine-induced changes in gamma-band oscillations: The contribution of parvalbumin and somatostatin interneurons.
Jessie Rademacher, Tineke Grent-'t-Jong, Davide Rivolta, Andreas Sauer, Bertram Scheller, Guillermo Gonzalez-Burgos, Christoph Metzner, Peter J Uhlhaas
PLoS Computational Biology June 9, 2025 DOI: 10.1371/journal.pcbi.1013118 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Within-subjects experimental study with placebo control Peer reviewed |
|---|---|
| Sample size | 12 |
| Population | Healthy volunteers |
| Intervention | Ketamine |
| Dose | sub-anesthetic dosages |
| Topics | Esketamine Ketamine |
| Keywords | Psychopharmacology Ketamine research Neural circuits Brain imaging |
| Citations | 2 |
| Key findings | Ketamine increases gamma-band power and flattens the aperiodic slope of resting-state MEG, with parvalbumin and somatostatin interneurons implicated in the gamma power increase but not the aperiodic change. |
Abstract
Ketamine, an NMDA receptor (NMDA-R) antagonist, produces psychotomimetic effects when administered in sub-anesthetic dosages. While previous research suggests that Ketamine alters the excitation/inhibition (E/I)-balance in cortical microcircuits, the precise neural mechanisms by which Ketamine produces these effects are not well understood. We analyzed resting-state MEG data from n = 12 participants who were administered Ketamine to assess changes in gamma-band (30-90 Hz) power and the slope of the aperiodic power spectrum compared to placebo. In addition, correlations of these effects with gene-expression of GABAergic interneurons and NMDA-Rs subunits were analyzed. Finally, we compared Ketamine-induced spectral changes to the effects of systematically changing NMDA-R levels on pyramidal cells, and parvalbumin-, somatostatin- and vasoactive intestinal peptide-expressing interneurons in a computational model of cortical layer-2/3 to identify crucial sites of Ketamine action. Ketamine resulted in a flatter aperiodic slope and increased gamma-band power across brain regions, with pronounced effects in prefrontal and central areas. These effects were correlated with the spatial distribution of parvalbumin and GluN2D gene expression. Computational modeling revealed that reduced NMDA-R activity in parvalbumin or somatostatin interneurons could reproduce increased gamma-band power by increasing pyramidal neuron firing rate, but did not account for changes in the aperiodic slope. The results suggest that parvalbumin and somatostatin interneurons may underlie increased gamma-band power following Ketamine administration in healthy volunteers, while changes in the aperiodic component could not be recreated. These findings have implications for current models of E/I-balance, as well as for understanding the mechanisms underlying the circuit effects of Ketamine.
Comparable studies
Other randomized controlled trials on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Healthy human subjects recruited from the community | 1994 | Randomized controlled trial | n = 19 |
| Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode | 2013 | Randomized controlled trial | n = 73 |
| Remifentanil-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine Patients undergoing major abdominal surgery | 2005 | Randomized controlled trial | n = 75 |
| Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures | 2014 | Randomized controlled trial | n = 41 |
| Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers Healthy volunteers | 2000 | Single-blind placebo-controlled study | n = 20 |
Citations in the library
Cites 16
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase Science December 6, 2007
and 11 more in the library